CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,875,448 | -52.5% | 322,509 | -41.4% | 0.06% | -53.3% |
| Q2 2023 | $18,678,770 | -5.3% | 550,509 | -7.6% | 0.14% | -1.5% |
| Q1 2023 | $19,721,491 | -9.4% | 595,509 | +21.9% | 0.14% | -6.8% |
| Q4 2022 | $21,771,826 | +85.1% | 488,509 | +16.7% | 0.15% | +77.1% |
| Q3 2022 | $11,765,000 | +50.1% | 418,509 | +43.9% | 0.08% | +27.7% |
| Q2 2022 | $7,839,000 | -17.1% | 290,794 | +4.8% | 0.06% | +1.6% |
| Q1 2022 | $9,451,000 | -36.8% | 277,481 | -28.3% | 0.06% | -32.6% |
| Q4 2021 | $14,962,000 | +53.8% | 387,221 | +114.9% | 0.10% | +43.9% |
| Q3 2021 | $9,730,000 | -27.2% | 180,222 | -54.9% | 0.07% | -27.5% |
| Q2 2021 | $13,365,000 | +130.7% | 399,685 | +16.1% | 0.09% | +89.6% |
| Q1 2021 | $5,792,000 | -3.9% | 344,139 | 0.0% | 0.05% | 0.0% |
| Q4 2020 | $6,030,000 | – | 344,139 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |